Your browser doesn't support javascript.
loading
Combined NK-CIK and PD-1 inhibitor (nivolumab), an effective immunotherapy for treating intrahepatic lymphoepithelioma-like cholangiocarcinoma unassociated with EBV infection: Two case reports and a literature review.
Sam Saji, Alen; Yang, Biao; Hou, Wan Ting; Liu, Xia; Ren, Qiu Ping; Wei, Yuan Feng; Zhang, Yu Zu; Yang, Xi.
Afiliación
  • Sam Saji A; Abdominal Oncology Ward, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
  • Yang B; Abdominal Oncology Ward, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
  • Hou WT; Department of Gastroenterology, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
  • Liu X; Abdominal Oncology Ward, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
  • Ren QP; Abdominal Oncology Ward, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
  • Wei YF; Department of Liver Surgery, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
  • Zhang YZ; Abdominal Oncology Ward, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
  • Yang X; Abdominal Oncology Ward, Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, China.
Front Oncol ; 13: 1090580, 2023.
Article en En | MEDLINE | ID: mdl-36865802
Intrahepatic lymphoepithelioma-like cholangiocarcinoma (LELCC) is a very rare malignant tumor arising from the biliary epithelium. To date, there has been a lack of evidence on the radiographical features, clinicopathological features, and treatment modalities of LELCC, with less than 28 cases of LELCC without Epstein-Barr virus (EBV) infection having been reported worldwide. The treatment of LELCC remains unexplored. Here, we present two cases of patients with LELCC without EBV infection who were treated by liver resection, chemotherapy, and immunotherapy and who achieved long survival time. The patients received surgery to remove the tumors and then adjuvant chemotherapy using the GS regimen and combined immunotherapy involving natural killer-cytokine-induced killer (NK-CIK) and nivolumab were performed. Both patients had a good prognosis with a survival time of more than 100 months and 85 months.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: China Pais de publicación: Suiza